Results 141 to 150 of about 2,133 (164)

Prurigo Nodularis

2016
Hugh Morris Gloster, Lauren E. Gebauer, Rachel L. Mistur   +2 more
  +4 more sources

Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study

EClinicalMedicine, 2023
Howard Sofen, Wei Jing Loo
exaly  

Prurigo nodularis

Der Hautarzt, 2014
S. Ständer, T. Mettang
openaire   +1 more source

Skin Microbiome in Prurigo Nodularis

International Journal of Molecular Sciences, 2023
Jakub Pawełczyk, Anna Zaczek, Magdalena Żychowska   +2 more
exaly  

Prurigo Nodularis: Moving Forward

Cutis, 2023
Ailish, Hanly, Kalman L, Watsky
openaire   +2 more sources

Molecular mechanisms of pruritus in prurigo nodularis

Frontiers in Immunology, 2023
Yiqi Zhu, Peng Lisi
exaly  

Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response

Journal of Dermatological Treatment, 2022
Husein Husein-Elahmed, Martin Steinhoff   +1 more
exaly  

Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis

Expert Review of Clinical Pharmacology, 2021
Pegah Bakhshi, Nishadh Sutaria, Justin Choi   +2 more
exaly  

Ethnic differences and comorbidities of 909 prurigo nodularis patients

Journal of the American Academy of Dermatology, 2018
, Emily Boozalis, Shivani Patel
exaly  

Real-World Prevalence of Prurigo Nodularis and Burden of Associated Diseases

Journal of Investigative Dermatology, 2020
Joseph Canner, Raveena Khanna, Sewon Kang   +2 more
exaly